Adjustment of the nominal value at Neovacs

Neovacs, a biopharmaceutical company listed on Euronext Growth Paris (ALNEV), has announced an adjustment to the par value of its shares. The decision, taken by the Board of Directors based on a resolution of June 2024, involves a capital reduction motivated by losses. The par value of the share now goes from €1 to €0.50.

This revaluation results in a change in the share capital, which goes from 269,590 euros to 134,795 euros, for a total of 269,590 shares. This initiative follows the dynamics of the company's financial adaptation to market conditions.

This maneuver comes in a context of dilutive financing, notably involving OCEANE-BSA and ORA, likely to create downward pressure on the share price. Neovacs invites investors to exercise vigilance before any investment.